mRNA-1050
Phase 1RNA therapy
ModernamRNA-1050 is one of 9 therapeutic programs targeting Lyme disease. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
14 competitors in Lyme Disease
#DrugCompanyPhaseTrials
1Achromycin V
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antabuse
TevaPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
VLA15
PfizerPhase 3
Psilocybin
COMPASS PathwaysPhase 1
Ceftriaxone Treatment
NNantes University Hospital
Phase 2
mRNA-1050
ModernaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-1050. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company